Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients

Autor:	Anil J. Trindade, Kaitlyn C. Chapin, Whitney D. Gannon, Haley Hoy, Caitlin T. Demarest, Eric S. Lambright, Katie A. McPherson, Stephanie G. Norfolk, Ivan M. Robbins, Matthew Bacchetta, David B. Erasmus, Ciara M. Shaver
Rok vydání:	2022
Předmět:	Transplantation Infectious Diseases SARS-CoV-2 Disease Progression Humans COVID-19 Lung Transplant Recipients
Zdroj:	Transplant infectious disease : an official journal of the Transplantation SocietyREFERENCES. 24(6)
ISSN:	1399-3062
Popis:	Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited.We performed a single-center, observational study of outcomes in lung transplant recipients diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre-Delta, 20 Delta, and 56 Omicron-era). Twenty-five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID-19 did not alter change in forced expiratory volume in 1 s (FEVThis study describes the natural history of SARS-CoV-2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS-CoV-2 is not associated with worsening lung function.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b8e7501df7448b9aa31bdc351a985ce https://pubmed.ncbi.nlm.nih.gov/36271645 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.